PerioRex^™

Advanced Oral Health · U.S. Partnership Opportunity

Business Development info@periorex.com
periorex.health

The Future of Periodontal Health Starts Here.

Science That Helps Protect Gums and Alveolar Bone

A large, underserved U.S. market

Periodontal disease is one of the most prevalent and economically burdensome chronic conditions in the United States. Prevalence rises sharply with age, and America's aging population is expanding the addressable market year over year.

90M+

Americans Affected

42%

Adults 30+

60%

Adults 65+

$154B

Annual Burden

Why PerioRex

Patent-Protected IPUS 10,022,412 B2 + patents in Korea & Japan. EU filing available for partners.

Human RCT ValidatedDouble-blind, placebo-controlled trial (n=94) at Ajou University & Seoul St. Mary's Hospital.

Government-RecognizedKorea MFDS functional ingredient recognition — approved claim: "may help alleviate gum condition."

Category WhitespaceDaily-use periodontal supplements with this evidence, IP, and regulatory endorsement are rare.

Product Specifications

Format60 capsules · daily

ActiveGovernment-approved complex

PatentUS 10,022,412 B2

ManufacturingGMP · Biofarm, Korea

RegulatoryMFDS Cert. 2025-13

R&DMedibio Lab Co., Ltd.

Clinical Evidence · 4 SCIE-Indexed Publications

RCT · 2024

Human RCT (n=94) in gingivitis Reductions in PGE₂, IL-1β, MMP-8, MMP-9. Nutrients, 16(17):3000

In Vitro · 2020

Anti-inflammatory + bone formation ↓IL-6, IL-8, PGE₂; ↑RUNX2, COL1A1, ALP. Food Science & Biotechnology, 29(4):539–548

Animal · 2019

Alveolar bone loss inhibition Ligature-induced periodontitis, 3-week oral. Int. J. Oral Biology, 44(2):55–61

Animal · 2021

Dose-response under 20× LPS stress 24.3% / 28.9% bone loss inhibition. Korean J. Dental Materials, 48(2):71–78

Partnership Pathways

Strategic Partnership

Long-term commercial with category leaders

Joint Venture

Co-invested U.S. commercialization

Private Label

Custom brand · Full regulatory package

Start the conversation Business Development · info@periorex.com
Developed by Medibio Lab Co., Ltd. (Korean R&D biotechnology) · Manufactured by Biofarm (GMP-certified) · Seoul, Korea

Available Under NDA Business plan · Scientific dossier · MFDS certificate · Patent documentation · Clinical trial reports · Financial projections

Statements on this page have not been evaluated by the U.S. Food and Drug Administration. PerioRex is not intended to diagnose, treat, cure, or prevent any disease. Market opportunity figures cited from CDC and NIDCR. U.S. Patent No. US 10,022,412 B2. MFDS Certificate No. 2025-13 (March 25, 2025).